Clinical trials: HIV-1
HIV-1-infection
MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy
This is a Phase 1, open-label single-center study to determine the safety of MGD014 in participants with human immunodeficiency virus (HIV) infection on stable suppressive antiretroviral therapy (ART).
- Trial name
- NCT03570918
- Testing
- MGD014
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- MacroGenics
Hepatitis C, HIV-1-infection
Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection
To achieve global hepatitis C virus (HCV) elimination by 2030, 80% of the ~71 million people with chronic HCV infection will need to be treated, necessitating simplification of treatment delivery and associated laboratory…
- Conditions
- Hepatitis C, HIV-1-infection, Liver Diseases
- Trial name
- MINMON (NCT03512210)
- Testing
- Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy
- Where
- 38 sites in United States, Brazil and 4 more
- Volunteers
- 400 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Infection, Human Immunodeficiency Virus
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
ING116070 is a Phase IIIb single-arm, open-label, multicenter study. The study will be conducted in approximately 14 HIV-1 infected antiretroviral therapy (ART)-naïve subjects.
- Trial name
- NCT01499199
- Testing
- Dolutegravir
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- ViiV Healthcare
Cardiovascular Disease
Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
The purpose of this study is to compare the cardiovascular profiles of efavirenz and rilpivirine, which are two drugs used to treat HIV infection.
- Trial name
- NCT01585038
- Testing
- Efavirenz, Rilpivirine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Indiana University
HIV Infection
Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
To evaluate the safety and efficacy of reformulated raltegravir (MK-0518) 1200 mg once daily in combination with TRUVADA™ versus raltegravir 400 mg twice daily in combination with TRUVADA™ in HIV-1 infected, treatment-naive…
- Trial name
- onceMRK (NCT02131233)
- Testing
- Reformulated Raltegravir, Raltegravir, TRUVADA™
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued baseline antiretroviral therapy (ART), through Week 48; and to evaluate the…
- Trial name
- NCT05631093
- Testing
- ART, DOR/ISL
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 553 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection, HCV Infection
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment
This study will evaluate efficacy of ledipasvir/sofosbuvir (LDV/SOF) and safety and tolerability of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or emtricitabine/rilpivirine/tenofovir…
- Trial name
- Co-STARs (NCT02707601)
- Testing
- E/C/F/TAF, F/R/TAF, LDV/SOF
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus Type 1 (HIV-1)
Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study
This study will assess the pharmacokinetics, safety, tolerability, maintenance of virological suppression and patient reported outcomes for participants receiving CAB and RPV LA injections following SC administration in the…
- Trial name
- NCT05896748
- Testing
- Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA)
- Where
- 30 sites in United States, Canada and 4 more
- Volunteers
- 94 people
- Sponsor
- ViiV Healthcare
HIV Infections
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm.
- Trial name
- NCT00090779
- Testing
- Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
- Where
- 27 sites in United States, Peru
- Volunteers
- 130 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1 Infection, Hepatitis C
12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
People who are infected with Hepatitis C Virus (HCV) have a great chance of being cured of the infection when they are treated with sofosbuvir.
- Trial name
- NCT02605304
- Testing
- Ledipasvir/sofosbuvir, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1 Infection
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
The purpose of this study is to evaluate pharmacokinetics (what body does to medication), safety, tolerability, and efficacy (effectiveness) of darunavir with low-dose ritonavir (DRV/rtv) administered once daily, in combination…
- Trial name
- DIONE (NCT00915655)
- Testing
- darunavir, ritonavir, zidovudine
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 12 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV, HIV Infections
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
The purpose of this study is to study how changes in the body during pregnancy influence the blood levels of TMC114 (darunavir) and ritonavir taken together, darunavir and cobicistat taken as a fixed-dose combination, TMC125…
- Conditions
- HIV, HIV Infections, Pregnancy
- Trial name
- NCT00855335
- Testing
- Darunavir, Ritonavir, Etravirine
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 77 people
- Sponsor
- Janssen Scientific Affairs, LLC
HIV Infections
Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV.
- Trial name
- NCT00084149
- Testing
- Abacavir sulfate, Lamivudine, and Zidovudine, Lopinavir/Ritonavir
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of dapivirine gel (0.05%) administered rectally to HIV-1 seronegative adults.
- Trial name
- NCT03239483
- Testing
- Dapivirine gel
- Where
- 3 sites in United States, Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
This study is designed to compare the efficacy and safety of simplifying therapy from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC)…
- Trial name
- ASSURE (NCT01102972)
- Testing
- Reyataz + Norvir + Truvada, Reyataz + Epzicom
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 297 people
- Sponsor
- ViiV Healthcare
HIV Infections
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response
The purpose of this study is to determine whether the addition of Pyridostigmine to Highly Active Antiretroviral Therapy (HAART) increases the number of CD4+ T-cells in discordant patients in which viral load diminishes, but…
- Trial name
- NCT00518154
- Testing
- Pyridostigmine tablets
- Where
- 2 sites in Mexico
- Volunteers
- 7 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
HIV-1-infection
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection
This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo once every two weeks administered via "IV Push" or intramuscular injection.
- Trial name
- NCT03913195
- Testing
- ibalizumab-uiyk
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
HIV-1 Infection
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
The study was done to: test a strategy of using a resistance test to choose anti-HIV drugs see how well combinations of new anti-HIV drugs work to lower HIV infection see if taking new anti-HIV drugs together is safe and…
- Trial name
- MULTI-OCTAVE (NCT01641367)
- Testing
- Darunavir, Etravirine, Emtricitabine/tenofovir disoproxil fumarate
- Where
- 19 sites in Brazil, Haiti and 8 more
- Volunteers
- 545 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia
The medicines used to treat HIV can suppress but cannot kill all the virus in the body. A small amount of virus remains at low levels in the part of the blood called the plasma.
- Trial name
- NCT00618371
- Testing
- Raltegravir (MK-0518)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
HIV Infection
Safety and Efficacy Study of Switching From Epzicom to Truvada
This protocol describes a prospective, randomized, open-label, multicenter study to evaluate the safety and efficacy of switching from fixed dose abacavir (ABC)/lamivudine (3TC) to fixed dose emtricitabine (FTC)/tenofovir…
- Trial name
- SWIFT (NCT00724711)
- Testing
- emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), abacavir (ABC)/lamivudine (3TC)
- Where
- 80 sites in United States, Canada and 1 more
- Volunteers
- 312 people
- Sponsor
- Gilead Sciences